131I-metaiodobenzylguanidine (131I-MIBG) is a norepinephrine analog that concentrates in
adrenergic tissue and therefore holds promise for cell-specific treatment of neuroblastoma.
This is a dual institution, Phase II study of 131I-MIBG administered at the previously
defined maximum practical dose of 18 mCi/kg to children with relapsed or refractory
Inclusion criteria: Refractory neuroblastoma with original diagnosis based on tumor
histopathology or elevated urine VMA with typical tumor cells in the bone marrow.